BACKGROUND: Artemisinin-based combination therapies are now widely recommended as first-line treatment for uncomplicated malaria. However, which therapies are optimal is a matter of debate. We aimed to compare the short- and longer-term efficacy of 2 leading therapies in a cohort of young Ugandan children. METHODS: A total of 351 children aged 6 weeks to 12 months were enrolled and followed up for up to 1 year. Children who were at least 4 months of age, weighted at least 5 kg, and had been diagnosed as having their first episode of uncomplicated malaria were randomized to receive artemether-lumefantrine or dihydroartemisinin-piperaquine. The same treatment was given for all subsequent episodes of uncomplicated malaria. Recrudescent and new infections were distinguished by polymerase chain reaction genotyping. Outcomes included the risk of recurrent malaria after individual treatments and the incidence of malaria treatments for individual children after randomization. RESULTS: A total of 113 children were randomized to artemether-lumefantrine and 119 to dihydroartemisinin-piperaquine, resulting in 320 and 351 treatments for uncomplicated falciparum malaria, respectively. Artemether-lumefantrine was associated with a higher risk of recurrent malaria after 28 days (35% vs 11%; P = .001]). When the duration of follow-up was extended, differences in the risk of recurrent malaria decreased such that the overall incidence of malaria treatments was similar for children randomized to artemether-lumefantrine, compared with those randomized to dihydroartemisinin-piperaquine (4.82 vs 4.61 treatments per person-year; P = .63). The risk of recurrent malaria due to recrudescent parasites was similarly low in both treatment arms. CONCLUSIONS: Artemether-lumefantrine and dihydroartemisinin-piperaquine were both efficacious and had similar long-term effects on the risk of recurrent malaria. Clinical trials registration. NCT00527800.
RCT Entities:
BACKGROUND:Artemisinin-based combination therapies are now widely recommended as first-line treatment for uncomplicated malaria. However, which therapies are optimal is a matter of debate. We aimed to compare the short- and longer-term efficacy of 2 leading therapies in a cohort of young Ugandan children. METHODS: A total of 351 children aged 6 weeks to 12 months were enrolled and followed up for up to 1 year. Children who were at least 4 months of age, weighted at least 5 kg, and had been diagnosed as having their first episode of uncomplicated malaria were randomized to receive artemether-lumefantrine or dihydroartemisinin-piperaquine. The same treatment was given for all subsequent episodes of uncomplicated malaria. Recrudescent and new infections were distinguished by polymerase chain reaction genotyping. Outcomes included the risk of recurrent malaria after individual treatments and the incidence of malaria treatments for individual children after randomization. RESULTS: A total of 113 children were randomized to artemether-lumefantrine and 119 to dihydroartemisinin-piperaquine, resulting in 320 and 351 treatments for uncomplicated falciparum malaria, respectively. Artemether-lumefantrine was associated with a higher risk of recurrent malaria after 28 days (35% vs 11%; P = .001]). When the duration of follow-up was extended, differences in the risk of recurrent malaria decreased such that the overall incidence of malaria treatments was similar for children randomized to artemether-lumefantrine, compared with those randomized to dihydroartemisinin-piperaquine (4.82 vs 4.61 treatments per person-year; P = .63). The risk of recurrent malaria due to recrudescent parasites was similarly low in both treatment arms. CONCLUSIONS:Artemether-lumefantrine and dihydroartemisinin-piperaquine were both efficacious and had similar long-term effects on the risk of recurrent malaria. Clinical trials registration. NCT00527800.
Authors: Abel Kakuru; Jane Achan; Mary K Muhindo; Gloria Ikilezi; Emmanuel Arinaitwe; Florence Mwangwa; Theodore Ruel; Tamara D Clark; Edwin Charlebois; Philip J Rosenthal; Diane Havlir; Moses R Kamya; Jordan W Tappero; Grant Dorsey Journal: Clin Infect Dis Date: 2014-04-23 Impact factor: 9.079
Authors: Roland A Cooper; Melissa D Conrad; Quentin D Watson; Stephanie J Huezo; Harriet Ninsiima; Patrick Tumwebaze; Samuel L Nsobya; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2015-06-01 Impact factor: 5.191
Authors: Abel Kakuru; Prasanna Jagannathan; Emmanuel Arinaitwe; Humphrey Wanzira; Mary Muhindo; Victor Bigira; Emmanuel Osilo; Jaco Homsy; Moses R Kamya; Jordan W Tappero; Grant Dorsey Journal: Am J Trop Med Hyg Date: 2013-02-04 Impact factor: 2.345
Authors: Joaniter Nankabirwa; Bonnie Cundill; Sian Clarke; Narcis Kabatereine; Philip J Rosenthal; Grant Dorsey; Simon Brooker; Sarah G Staedke Journal: PLoS One Date: 2010-10-19 Impact factor: 3.240
Authors: Darren J Creek; Victor Bigira; Shelley McCormack; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Jordan W Tappero; Taylor G Sandison; Niklas Lindegardh; Francois Nosten; Francesca T Aweeka; Sunil Parikh Journal: J Infect Dis Date: 2013-02-27 Impact factor: 5.226
Authors: Shereen Katrak; Anne Gasasira; Emmanuel Arinaitwe; Abel Kakuru; Humphrey Wanzira; Victor Bigira; Taylor G Sandison; Jaco Homsy; Jordan W Tappero; Moses R Kamya; Grant Dorsey Journal: Malar J Date: 2009-11-30 Impact factor: 2.979